TRGNF News and Press, Transgene S.A. From 04/18/23

- New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation - In the head and neck cancer trial to date, all patients treated with TG4050 have remained disease-free...

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC) Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that design...

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms. Carol Stuckley, MBA, as an independent Director of the Company. This appointment re...

Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies , announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is ...

Webinar to be held Wednesday, April 19, 2023 at 12:00 pm ET / 6:00 pm CET Regulatory News: TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will host a virtual Key Opinion Leader (KOL)...

Regulatory News: TRANSGENE (Paris: TNG) , a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in several investor events, as set out below. The Future of Oncology Symposium , ...

Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum - TG4050: New Phase I data confirm the strong clinical and commercial potential o...

New Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation Exciting preclinical data on the novel IV oncolytic virus candidate TG6050 Regulatory News: ...

Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors. “John and Pedr...

TG6050 is a proprietary oncolytic virus derived from Transgene’s Invir.IO™ platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody. The Phase I trial, named Delivir, will evaluate the intravenous (IV) administration of this novel multi-armed immunotherapy in patients...